Determination of Myloid Antigen Expression on Childhood Acute Lymphoblastic Leukaemia Cells: Discrepancies Using Different Monoclonal Antibody Clones

Prospective clinical studies including large numbers of patients have led to the conclusion that co-expression of myeloid antigens in childhood acute lymphoblastic leukaemia (My+ ALL) does not have prognostic significance. However, reports of the frequency of My+ ALL in children vary widely across laboratories using different mAb clones and staining and analysing procedures. Taking two commonly accepted thresholds of positivity for myeloid antigens (20 and 30%), we analysed the immunoreactivity of the most widely employed mAb clones against CD13 (SJ1D1, L138 and My7) and CD33 (My9, P67.6 and D3HL60) and compared the proportions of My+ ALL detected by these clones in childhood ALL. The correlation between myeloid antigen expression and the presence of the t(12;21) translocation was analysed concomitantly in the same samples. The percentage of ALL cases positive for myeloid markers varied significantly depending on the mAb clone and the positive threshold. Among patients with B-ALL, the proportion of CD13+ ALL was significantly lower using SJ1D1 than using L138 or My7, while the proportion of CD33+ ALL was significantly higher for My9 than for P67.6 or D3HL60. Analysis of the co-expression of CD13 and CD33 on B-ALL cells using combinations of mAb clones showed that this frequency was either underestimated by the SJ1D1/D3HL60 or overestimated by the L138/P67.6 and My7/My9 combinations. A correlation between CD13/CD33 positivity and the t(12;21) translocation was uniformly observed in B-ALL patients for a positive threshold of 30%, whereas SJ1D1/D3HL60 detected no correlation between t(12;21) and CD13/CD33 ppositivity when the threshold was lowered to 20%. These data show that the mAb clones commonly used to detect the CD13 and CD33 surface antigens have variable immunoreactivity against childhood ALL cells, which may partly explain the conflicting reports concerning the prognostic significance of myeloid antigen expression in paediatric ALL and its association with different translocations. The present findings may also be of clinical importance for therapeutic choices.

[1]  J. Downing,et al.  Reappraisal of the clinical and biologic significance of myeloid-associated antigen expression in childhood acute lymphoblastic leukemia. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  R. Consolini,et al.  Expression of myeloid markers lacks prognostic impact in children treated for acute lymphoblastic leukemia: Italian experience in AIEOP-ALL 88-91 studies. , 1998, Blood.

[3]  F. Sigaux,et al.  The majority of myeloid‐antigen‐positive (My+) childhood B‐cell precursor acute lymphoblastic leukaemias express TEL‐AML1 fusion transcripts , 1997, British journal of haematology.

[4]  Maria Grazia Valsecchi,et al.  Incidence and clinical relevance of TEL/AML1 fusion genes in children with acute lymphoblastic leukemia enrolled in the German and Italian multicenter therapy trials , 1997 .

[5]  H. Sather,et al.  Clinical features and treatment outcome of children with myeloid antigen positive acute lymphoblastic leukemia: a report from the Children's Cancer Group. , 1997, Blood.

[6]  A. Look,et al.  Prognostic significance of fluorescence intensity of surface marker expression in childhood B-precursor acute lymphoblastic leukemia. A Pediatric Oncology Group Study. , 1997, Blood.

[7]  F. Sigaux,et al.  Immunophenotype of adult acute lymphoblastic leukemia, clinical parameters, and outcome: an analysis of a prospective trial including 562 tested patients (LALA87). French Group on Therapy for Adult Acute Lymphoblastic Leukemia. , 1994, Blood.

[8]  G. Martinelli,et al.  Increased expression of myeloid antigen markers in adult acute lymphoblastic leukaemia patients: diagnostic and prognostic implications , 1994, British journal of haematology.

[9]  A. Baruchel,et al.  Use of immunophenotype as part of the prognostic stratification for childhood ALL in the FRALLE 93 protocol. , 1994, Leukemia & lymphoma.

[10]  R. Foà,et al.  Co‐expression of myeloid antigens in childhood acute lymphoblastic leukaemia: relationship with the stage of differentiation and clinical significance , 1991, British journal of haematology.

[11]  E. Thiel,et al.  Review of the incidence and clinical relevance of myeloid antigen-positive acute lymphoblastic leukemia. , 1991, Leukemia.

[12]  F. Davey,et al.  Significance of aberrant immunophenotypes in childhood acute lymphoid leukemia , 1991, Cancer.

[13]  K. Weinberg,et al.  Clinical importance of myeloid-antigen expression in acute lymphoblastic leukemia of childhood. , 1991, The New England journal of medicine.

[14]  D. Treille,et al.  Myeloid surface antigen expression in adult acute lymphoblastic leukemia. , 1990, Leukemia.

[15]  F. Behm,et al.  14q32 translocations are associated with mixed-lineage expression in childhood acute leukemia. , 1990, Blood.

[16]  E. Montserrat,et al.  Clinical significance of the presence of myeloid associated antigens in acute lymphoblastic leukaemia , 1990, British journal of haematology.

[17]  F. Behm,et al.  Myeloid-associated antigen expression lacks prognostic value in childhood acute lymphoblastic leukemia treated with intensive multiagent chemotherapy. , 1990, Blood.

[18]  J. Reuben,et al.  Myeloid surface antigen-positive acute lymphoblastic leukemia (My+ ALL): immunophenotypic, ultrastructural, cytogenetic, and molecular characteristics. , 1989, Leukemia.

[19]  I Royston,et al.  Clinical importance of myeloid antigen expression in adult acute lymphoblastic leukemia. , 1987, The New England journal of medicine.

[20]  C. Pui,et al.  Acute mixed lineage leukemia: clinicopathologic correlations and prognostic significance. , 1985, Blood.

[21]  H. Gralnick,et al.  The Morphological Classification of Acute Lymphoblastic Leukaemia: Concordance among Observers and Clinical Correlations , 1981, British journal of haematology.